Articles published by Biogen Inc.
Biogen Board Appoints Two New Independent Directors
September 12, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
July 26, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
December 19, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Biogen Appoints Monish Patolawala to its Board of Directors
November 06, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
October 19, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
September 29, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.